title: Re: Raloxifene and stroke risks in Japanese postmenopausal women with osteoporosis on postmarketing surveillance.
authors.affiliation: Lilly Research Laboratories Development Center of Excellence Japan Eli Lilly Japan KK Kobe, Japan.
authors.forename: Etsuro
authors.initials: E
authors.lastname: Hamaya
authors.forename: Hideaki
authors.initials: H
authors.lastname: Sowa
mesh_terms: D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D017698:Postmenopause; D020849:Raloxifene Hydrochloride / Q000009:adverse effects*; D020521:Stroke
chemical_list: D050071:Bone Density Conservation Agents; D020849:Raloxifene Hydrochloride